Patents by Inventor Krzysztof SZYMCZAK

Krzysztof SZYMCZAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazole[1,5-a] pyrimidine derivatives as kinase JAK inhibitors
    Patent number: 11072619
    Abstract: A compound or its acid addition salt of the general formula (I), wherein R1 represents phenyl substituted with one or two substituents selected from the group consisting of halogen and C1-C3 alkoxyl, or 6-membered heteroaryl with 1 or 2 nitrogen atoms, which is unsubstituted or substituted with a substituent selected from the group consisting of —NH2, halogen, alkyl C1-C4, alkoxyl C1-C3, and 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from the group consisting of N and O. The compound has the activity of kinase JAK1/JAK3 inhibitor and can find use in the treatment of chronic inflammatory and autoimmunological diseases.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: July 27, 2021
    Assignee: Celon Pharma S.A.
    Inventors: Michal Mroczkiewicz, Bartosz Stypik, Anna Bujak, Krzysztof Szymczak, Pawel Gunerka, Krzysztof Dubiel, Maciej Wieczorek, Jerzy Pieczykolan
  • PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES AS KINASE JAK INHIBITORS
    Publication number: 20200199128
    Abstract: A compound or its acid addition salt of the general formula (I), wherein R1 represents phenyl substituted with one or two substituents selected from the group consisting of halogen and C1-C3 alkoxyl, or 6-membered heteroaryl with 1 or 2 nitrogen atoms, which is unsubstituted or substituted with a substituent selected from the group consisting of —NH2, halogen, alkyl C1-C4, alkoxyl C1-C3, and 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from the group consisting of N and O. The compound has the activity of kinase JAK1/JAK3 inhibitor and can find use in the treatment of chronic inflammatory and autoimmunological diseases.
    Type: Application
    Filed: May 10, 2018
    Publication date: June 25, 2020
    Applicant: CELON PHARMA S.A.
    Inventors: Michal MROCZKIEWICZ, Bartosz STYPIK, Anna BUJAK, Krzysztof SZYMCZAK, Pawel GUNERKA, Krzysztof DUBIEL, Maciej WIECZOREK, Jerzy PIECZYKOLAN